Table 3 Dose response series for local control and late effects
From: Conventional fractionation should not be the standard of care for T2 glottic cancer
Series | Total Dose (Gy) | Dose per fraction (Gy) | OTT (days) | BED10a(Gy) | 5-year LC (%) | BED3 (Gy) | Late effects (%) |
|---|---|---|---|---|---|---|---|
Current series, 2017 | 52.5 | 3.28 | 22 | 69.7 | 82 | 110 | 1.8 |
Ermis, 2015 [10] | 55 | 2.75 | 28 | 67.1 | 81 | 105 | 1.6 |
Motegi, 2015 [15] | 64.8 | 2.4 | 37 | 68.4 | 77 | 117 | 4.5b |
Berwouts, 2015 [16] | 70 | 2 | 47 | 62.0 | 75 | 117 | nr |
Trotti, 2014 [17] | 79.2 | 1.2 | 45 | 68.7 | 78 | 111 | 4.2 |
Trotti, 2014 [17] | 70 | 2 | 47 | 62.0 | 70 | 117 | 2.5 |
Karasawa, 2013 [41] | 63 | 2.25 | 41 | 61.2 | 69 | 110 | 0.0 |
Chera, 2010 [9] | 65.3 | 2.25 | 39 | 65.9 | 76 | 114 | 1.2 |
Garden, 2003 [7] | 70 | 2 | 47 | 62.0 | 72 | 117 | 2.6 |
Warde, 1998 [5] | 50 | 2.5 | 28 | 59.5 | 69 | 92 | nr |